Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients.

Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T.

Ann Neurol. 2020 Feb 13. doi: 10.1002/ana.25701. [Epub ahead of print]

PMID:
32056253
2.

Familial aggregation and heritability of ankylosing spondylitis - a Swedish nested case-control study.

Morin M, Hellgren K, Frisell T.

Rheumatology (Oxford). 2019 Nov 5. pii: kez519. doi: 10.1093/rheumatology/kez519. [Epub ahead of print]

PMID:
31687771
3.

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T.

JAMA Neurol. 2019 Oct 7. doi: 10.1001/jamaneurol.2019.3365. [Epub ahead of print]

PMID:
31589278
4.

Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS.

Granqvist M, Burman J, Gunnarsson M, Lycke J, Nilsson P, Olsson T, Sundström P, Svenningsson A, Vrethem M, Frisell T, Piehl F.

Mult Scler. 2019 Aug 8:1352458519866600. doi: 10.1177/1352458519866600. [Epub ahead of print]

PMID:
31392923
5.

Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply.

Frisell T, Askling J.

Rheumatology (Oxford). 2019 Aug 1;58(8):1510-1511. doi: 10.1093/rheumatology/kez120. No abstract available.

PMID:
31056707
6.

Violent crime among Swedish military veterans after deployment to Afghanistan: a population-based matched cohort study.

Pethrus CM, Frisell T, Reutfors J, Johansson K, Neovius K, Söderling JK, Bruze G, Neovius M.

Int J Epidemiol. 2019 Oct 1;48(5):1604-1613. doi: 10.1093/ije/dyz084.

7.

Response to: 'Inflammatory and non-inflammatory triggers of acute coronary syndromes' by Eyuboglu.

Westerlind H, Holmqvist M, Ljung L, Frisell T, Askling J.

Ann Rheum Dis. 2019 Mar 28. pii: annrheumdis-2019-215293. doi: 10.1136/annrheumdis-2019-215293. [Epub ahead of print] No abstract available.

PMID:
30923234
8.

Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply.

Frisell T, Askling J.

Rheumatology (Oxford). 2019 Aug 1;58(8):1507-1509. doi: 10.1093/rheumatology/kez067. No abstract available.

PMID:
30838417
9.

Siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome.

Westerlind H, Holmqvist M, Ljung L, Frisell T, Askling J.

Ann Rheum Dis. 2019 May;78(5):683-687. doi: 10.1136/annrheumdis-2018-214828. Epub 2019 Feb 20.

PMID:
30787006
10.

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.

Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, Lycke J, Piehl F, Salzer J.

Eur J Neurol. 2019 Aug;26(8):1060-1067. doi: 10.1111/ene.13936. Epub 2019 Mar 12.

PMID:
30762259
11.

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.

Alping P, Piehl F, Langer-Gould A, Frisell T; COMBAT-MS Study Group.

Epidemiology. 2019 Mar;30(2):230-233. doi: 10.1097/EDE.0000000000000948.

12.

Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register.

Frisell T, Dehlin M, Di Giuseppe D, Feltelius N, Turesson C, Askling J; ARTIS Study Group .

Rheumatology (Oxford). 2019 Jan 21. doi: 10.1093/rheumatology/key433. [Epub ahead of print]

PMID:
30668875
13.

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.

Chatzidionysiou K, Hetland ML, Frisell T, Di Giuseppe D, Hellgren K, Glintborg B, Nordström D, Aaltonen K, Törmänen MR, Klami Kristianslund E, Kvien TK, Provan SA, Björn Guðbjörnsson B, Dreyer L, Kristensen LE, Jørgensen TS, Jacobsson L, Askling J.

RMD Open. 2018 Apr 12;4(1):e000655. doi: 10.1136/rmdopen-2018-000655. eCollection 2018. Review. Erratum in: RMD Open. 2018 May 14;4(1):.

14.

Concordance of Non-Low-Risk Disease Among Pairs of Brothers With Prostate Cancer.

Jansson F, Drevin L, Frisell T, Stattin P, Bratt O, Akre O.

J Clin Oncol. 2018 Jun 20;36(18):1847-1852. doi: 10.1200/JCO.2017.76.6907. Epub 2018 Apr 13.

PMID:
29652556
15.

Uptake of rheumatology biosimilars in the absence of forced switching.

Di Giuseppe D, Frisell T, Ernestam S, Forsblad-D'Elia H, Lindqvist E, Lindström U, Sjöwall C, Askling J; ARTIS group.

Expert Opin Biol Ther. 2018 May;18(5):499-504. doi: 10.1080/14712598.2018.1458089. Epub 2018 Apr 10.

16.

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.

Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F.

JAMA Neurol. 2018 Mar 1;75(3):320-327. doi: 10.1001/jamaneurol.2017.4011.

17.

Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.

Frisell T, Baecklund E, Bengtsson K, Di Giuseppe D, Forsblad-d'Elia H, Askling J; ARTIS Study group.

Ann Rheum Dis. 2018 May;77(5):650-657. doi: 10.1136/annrheumdis-2017-212395. Epub 2017 Dec 13.

18.

Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme.

Yamanaka H, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Novelli Horne L, Inoue E, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SMM, Wesby-van Swaay E, Nyberg F.

RMD Open. 2017 Oct 10;3(2):e000498. doi: 10.1136/rmdopen-2017-000498. eCollection 2017.

19.

Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.

Wadström H, Frisell T, Askling J; Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.

JAMA Intern Med. 2017 Nov 1;177(11):1605-1612. doi: 10.1001/jamainternmed.2017.4332.

20.

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.

Spelman T, Frisell T, Piehl F, Hillert J.

Mult Scler. 2018 Jul;24(8):1087-1095. doi: 10.1177/1352458517713668. Epub 2017 Jun 26.

PMID:
28649912
21.

Apgar Score Components at 5 Minutes: Risks and Prediction of Neonatal Mortality.

Cnattingius S, Norman M, Granath F, Petersson G, Stephansson O, Frisell T.

Paediatr Perinat Epidemiol. 2017 Jul;31(4):328-337. doi: 10.1111/ppe.12360. Epub 2017 May 11.

PMID:
28493508
22.

A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort study.

Jiang X, Askling J, Saevarsdottir S, Padyukov L, Alfredsson L, Viatte S, Frisell T.

Arthritis Res Ther. 2016 Dec 3;18(1):288.

23.

Reply.

Alping P, Frisell T, Svenningsson A, Piehl F.

Ann Neurol. 2016 Nov;80(5):791-792. doi: 10.1002/ana.24767. Epub 2016 Sep 27. No abstract available.

PMID:
27553863
24.

Carryover Effects in Sibling Comparison Designs.

Sjölander A, Frisell T, Kuja-Halkola R, Öberg S, Zetterqvist J.

Epidemiology. 2016 Nov;27(6):852-8. doi: 10.1097/EDE.0000000000000541.

PMID:
27488059
25.

How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins.

Hensvold AH, Frisell T, Magnusson PK, Holmdahl R, Askling J, Catrina AI.

Ann Rheum Dis. 2017 Jan;76(1):119-125. doi: 10.1136/annrheumdis-2015-208980. Epub 2016 Apr 28.

PMID:
27125521
26.

Family history of rheumatoid arthritis: an old concept with new developments.

Frisell T, Saevarsdottir S, Askling J.

Nat Rev Rheumatol. 2016 Jun;12(6):335-43. doi: 10.1038/nrrheum.2016.52. Epub 2016 Apr 21. Review.

PMID:
27098907
27.

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.

Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, Axelsson M, Malmeström C, Fink K, Lycke J, Svenningsson A, Piehl F.

Ann Neurol. 2016 Jun;79(6):950-8. doi: 10.1002/ana.24651. Epub 2016 Apr 20.

PMID:
27038238
28.

Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.

Michaud K, Berglind N, Franzén S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Nyberg F, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Askling J.

Ann Rheum Dis. 2016 Oct;75(10):1797-805. doi: 10.1136/annrheumdis-2015-208698. Epub 2016 Feb 8.

PMID:
26857699
29.

Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.

Wadström H, Frisell T, Sparén P, Askling J; ARTIS study group.

Ann Rheum Dis. 2016 Jul;75(7):1272-8. doi: 10.1136/annrheumdis-2015-208263. Epub 2016 Jan 11.

PMID:
26755797
30.

How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.

Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Michaud K, Nyberg F, Pappas DA, Reed G, Tanaka E, Tran TN, Verstappen SM, Yamanaka H, Wesby-van Swaay E, Symmons D.

Ann Rheum Dis. 2016 Oct;75(10):1789-96. doi: 10.1136/annrheumdis-2015-208105. Epub 2015 Nov 30.

PMID:
26621482
31.

New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis.

Lee SH, Byrne EM, Hultman CM, Kähler A, Vinkhuyzen AA, Ripke S, Andreassen OA, Frisell T, Gusev A, Hu X, Karlsson R, Mantzioris VX, McGrath JJ, Mehta D, Stahl EA, Zhao Q, Kendler KS, Sullivan PF, Price AL, O'Donovan M, Okada Y, Mowry BJ, Raychaudhuri S, Wray NR; Schizophrenia Working Group of the Psychiatric Genomics Consortium and Rheumatoid Arthritis Consortium International; Schizophrenia Working Group of the Psychiatric Genomics Consortium Authors, Byerley W, Cahn W, Cantor RM, Cichon S, Cormican P, Curtis D, Djurovic S, Escott-Price V, Gejman PV, Georgieva L, Giegling I, Hansen TF, Ingason A, Kim Y, Konte B, Lee PH, McIntosh A, McQuillin A, Morris DW, Nöthen MM, O'Dushlaine C, Olincy A, Olsen L, Pato CN, Pato MT, Pickard BS, Posthuma D, Rasmussen HB, Rietschel M, Rujescu D, Schulze TG, Silverman JM, Thirumalai S, Werge T; Schizophrenia Working Group of the Psychiatric Genomics Consortium Collaborators, Agartz I, Amin F, Azevedo MH, Bass N, Black DW, Blackwood DH, Bruggeman R, Buccola NG, Choudhury K, Cloninger RC, Corvin A, Craddock N, Daly MJ, Datta S, Donohoe GJ, Duan J, Dudbridge F, Fanous A, Freedman R, Freimer NB, Friedl M, Gill M, Gurling H, De Haan L, Hamshere ML, Hartmann AM, Holmans PA, Kahn RS, Keller MC, Kenny E, Kirov GK, Krabbendam L, Krasucki R, Lawrence J, Lencz T, Levinson DF, Lieberman JA, Lin DY, Linszen DH, Magnusson PK, Maier W, Malhotra AK, Mattheisen M, Mattingsdal M, McCarroll SA, Medeiros H, Melle I, Milanova V, Myin-Germeys I, Neale BM, Ophoff RA, Owen MJ, Pimm J, Purcell SM, Puri V, Quested DJ, Rossin L, Ruderfer D, Sanders AR, Shi J, Sklar P, St Clair D, Stroup TS, Van Os J, Visscher PM, Wiersma D, Zammit S; Rheumatoid Arthritis Consortium International Authors, Bridges SL Jr, Choi HK, Coenen MJ, de Vries N, Dieud P, Greenberg JD, Huizinga TW, Padyukov L, Siminovitch KA, Tak PP, Worthington J; Rheumatoid Arthritis Consortium International Collaborators, De Jager PL, Denny JC, Gregersen PK, Klareskog L, Mariette X, Plenge RM, van Laar M, van Riel P.

Int J Epidemiol. 2015 Oct;44(5):1706-21.

32.

Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries.

Verstappen SM, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Holmqvist M, Horne L, Lampl K, Michaud K, Nyberg F, Pappas DA, Reed G, Symmons DP, Tanaka E, Tran TN, Yamanaka H, Ho M.

Arthritis Care Res (Hoboken). 2015 Dec;67(12):1637-45. doi: 10.1002/acr.22661.

33.

Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study.

Mantel Ä, Holmqvist M, Nyberg F, Tornling G, Frisell T, Alfredsson L, Askling J.

Arthritis Rheumatol. 2015 Nov;67(11):2845-54. doi: 10.1002/art.39267.

34.

Does a family history of RA influence the clinical presentation and treatment response in RA?

Frisell T, Saevarsdottir S, Askling J.

Ann Rheum Dis. 2016 Jun;75(6):1120-5. doi: 10.1136/annrheumdis-2015-207670. Epub 2015 Jun 19.

PMID:
26091906
35.

Maternal body mass index during early pregnancy, gestational weight gain, and risk of autism spectrum disorders: Results from a Swedish total population and discordant sibling study.

Gardner RM, Lee BK, Magnusson C, Rai D, Frisell T, Karlsson H, Idring S, Dalman C.

Int J Epidemiol. 2015 Jun;44(3):870-83. doi: 10.1093/ije/dyv081. Epub 2015 Jun 4.

36.

Prolonged second stage of labor is associated with low Apgar score.

Altman M, Sandström A, Petersson G, Frisell T, Cnattingius S, Stephansson O.

Eur J Epidemiol. 2015 Nov;30(11):1209-15. doi: 10.1007/s10654-015-0043-4. Epub 2015 May 26.

PMID:
26008749
37.

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.

Frisell T, Forsberg L, Nordin N, Kiesel C, Alfredsson L, Askling J, Hillert J, Olsson T, Piehl F.

Mult Scler. 2016 Jan;22(1):85-93. doi: 10.1177/1352458515579216. Epub 2015 Apr 28.

PMID:
25921036
38.

Sexual offending runs in families: A 37-year nationwide study.

Långström N, Babchishin KM, Fazel S, Lichtenstein P, Frisell T.

Int J Epidemiol. 2015 Apr;44(2):713-20.

39.

Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden.

Frisell T, Hellgren K, Alfredsson L, Raychaudhuri S, Klareskog L, Askling J.

Ann Rheum Dis. 2016 Jan;75(1):183-9. doi: 10.1136/annrheumdis-2014-206133. Epub 2014 Dec 12.

40.

To what extent is the familial risk of rheumatoid arthritis explained by established rheumatoid arthritis risk factors?

Jiang X, Frisell T, Askling J, Karlson EW, Klareskog L, Alfredsson L, Källberg H.

Arthritis Rheumatol. 2015 Feb;67(2):352-62. doi: 10.1002/art.38927.

41.

Anabolic androgenic steroids and violent offending: confounding by polysubstance abuse among 10,365 general population men.

Lundholm L, Frisell T, Lichtenstein P, Långström N.

Addiction. 2015 Jan;110(1):100-8. doi: 10.1111/add.12715. Epub 2014 Nov 4.

PMID:
25170826
42.

Genetic contribution to postpartum haemorrhage in Swedish population: cohort study of 466,686 births.

Oberg AS, Hernandéz-Diaź S, Frisell T, Greene MF, Almqvist C, Bateman BT.

BMJ. 2014 Aug 13;349:g4984. doi: 10.1136/bmj.g4984.

43.

TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.

Raaschou P, Frisell T, Askling J; ARTIS Study Group.

Ann Rheum Dis. 2015 Dec;74(12):2137-43. doi: 10.1136/annrheumdis-2014-205745. Epub 2014 Aug 8.

PMID:
25107559
44.

The association between schizophrenia and rheumatoid arthritis: a nationwide population-based Swedish study on intraindividual and familial risks.

Sellgren C, Frisell T, Lichtenstein P, Landèn M, Askling J.

Schizophr Bull. 2014 Nov;40(6):1552-9. doi: 10.1093/schbul/sbu054. Epub 2014 Apr 8.

45.

Association of height and violent criminality: results from a Swedish total population study.

Beckley AL, Kuja-Halkola R, Lundholm L, Långström N, Frisell T.

Int J Epidemiol. 2014 Jun;43(3):835-42. doi: 10.1093/ije/dyt274. Epub 2014 Jan 22.

PMID:
24453240
46.

Hospital admission with infection during childhood and risk for psychotic illness--a population-based cohort study.

Blomström Å, Karlsson H, Svensson A, Frisell T, Lee BK, Dal H, Magnusson C, Dalman C.

Schizophr Bull. 2014 Nov;40(6):1518-25. doi: 10.1093/schbul/sbt195. Epub 2013 Dec 23.

47.

The 1% of the population accountable for 63% of all violent crime convictions.

Falk O, Wallinius M, Lundström S, Frisell T, Anckarsäter H, Kerekes N.

Soc Psychiatry Psychiatr Epidemiol. 2014 Apr;49(4):559-71. doi: 10.1007/s00127-013-0783-y. Epub 2013 Oct 31.

48.

Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age.

Frisell T, Holmqvist M, Källberg H, Klareskog L, Alfredsson L, Askling J.

Arthritis Rheum. 2013 Nov;65(11):2773-82. doi: 10.1002/art.38097.

49.

Maternal and fetal genetic contributions to postterm birth: familial clustering in a population-based sample of 475,429 Swedish births.

Oberg AS, Frisell T, Svensson AC, Iliadou AN.

Am J Epidemiol. 2013 Mar 15;177(6):531-7. doi: 10.1093/aje/kws244. Epub 2013 Feb 20.

PMID:
23425630
50.

Is the association between general cognitive ability and violent crime caused by family-level confounders?

Frisell T, Pawitan Y, Långström N.

PLoS One. 2012;7(7):e41783. doi: 10.1371/journal.pone.0041783. Epub 2012 Jul 24.

Supplemental Content

Loading ...
Support Center